Rene Verloes
Beerse, VLG 2340, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
PrEP-001 prophylactic effect against rhinovirus and influenza virus - RESULTS of 2 randomized trials.
Journal: Antiviral research
Published: February 02, 2018
Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study.
Journal: The Journal of infectious diseases
Published: January 17, 2018
Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus: Results from a Phase I, Double-Blind, Randomized, Placebo-Controlled First-in-Human Study in Healthy Adult Subjects.
Journal: Clinical pharmacokinetics
Published: February 27, 2017
Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845.
Journal: Virology journal
Published: December 05, 2016
Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection.
Journal: BMC gastroenterology
Published: October 06, 2016
Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers.
Journal: HIV medicine
Published: December 02, 2014
Safety and pharmacokinetics of the HIV-1 protease inhibitor TMC310911 coadministered with ritonavir in healthy participants: results from 2 phase 1 studies.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: October 15, 2013
Antiviral activity, pharmacokinetics, and safety of the HIV-1 protease inhibitor TMC310911, coadministered with ritonavir, in treatment-naive HIV-1-infected patients.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: October 15, 2013
In vivo evaluation of antiviral compounds on respiratory syncytial virus using a juvenile vervet monkey (Chlorocebus pygerythrus) infection model.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: July 04, 2013
Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy.
Journal: Gastroenterology
Published: December 14, 2011
Last Updated: 09/26/2026